Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Valion BioVBIO +2.76%23 Pretax Margin % is % as of Mar. 2026. GuruFocus rates VBIO with a GF Score™ of 23/100. The stock has 1 warning sign investors should review. Among 944 Biotechnology companies, Valion Bio ranks better than 99.79% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Valion Bio's Pre-Tax Income for the
three
months ended in Mar. 2026 was $-6.23 Mil. Valion Bio's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Therefore, Valion Bio's pretax margin for the quarter that ended in Mar. 2026 was %.
The historical rank and industry rank for Valion Bio's Pretax Margin % or its related term are showing as below:
VBIO'
s Pretax Margin % Range Over the Past 10 Years
Min: -987.14 Med: -675.74 Max: 18165.71
Current: 18165.71
VBIO's Pretax Margin % is ranked better than 99.79% of 944
companies
in the Biotechnology industry
Industry Median: -90.5
vs VBIO: 18165.71
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Valion Bio Pretax Margin % Related Terms
Valion Bio Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Valion Bio's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VBIO vs ZVSA, LYRA, ATXI: Pretax Margin % Comparison
For the Biotechnology subindustry, Valion Bio's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valion Bio Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Valion Bio's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Valion Bio's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valion Bio (VBIO) has a Pretax Margin % of % as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Valion Bio and its competitors. According to the industry distribution chart, Valion Bio ranks #2 out of 944 companies in the Biotechnology industry, placing it in the top 0.2%.
Is Valion Bio's Pretax Margin % too high?
Valion Bio's current Pretax Margin % is %. Based on the distribution chart, Valion Bio ranks #2 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Valion Bio has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Valion Bio's Pretax Margin % compare to ZVSA and LYRA?
According to the Biotechnology industry distribution chart, Valion Bio ranks #2 out of 944 companies for Pretax Margin %. This places Valion Bio in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Valion Bio and its competitors. Valion Bio's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valion Bio stock overvalued right now?
Valion Bio (VBIO) has a current Pretax Margin % of %. The current Pretax Margin % is %. Valion Bio's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Valion Bio (VBIO), the current Pretax Margin % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.
23GF Score
Get the complete analysis for VBIO
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VBIO has been successfully added to your 
